中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 10
Oct.  2011
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2011  >  27(10): 1116-1120

The role of high mobility group box 1 in human liver diseases

Research funding:

 

  • Published Date: 2011-10-20
    Abstract
  • High mobility group box 1 (HMGB1) is an enriched non-histone, chromatin-associated nuclear protein.During cell damage and inflammation HMGB1 can be extracellularly released by ways of active secretion and passive diffusion.Recent studies shows that HMGB1 may act as an inflammatory factor and an endogenous damage-associated molecular pattern recognized by its receptors, mediates liver inflammation, injury, fibrogenesis, as well as oncogenesis and tumor immune response.This review introduces the structure, function of HMGB1 and its role in human liver diseases.

     

    • FullText(HTML)
    • References(80)
  • [1]Park JS, Svetkauskaite D, He Q, et al.Involvement of toll-like receptors 2 and 4 in cellular activation by high mobilitygroup box 1 protein[J].J Biol Chem, 2004, 279 (9) :7370-7377.
    [1]Park JS, Svetkauskaite D, He Q, et al.Involvement of toll-like receptors 2 and 4 in cellular activation by high mobilitygroup box 1 protein[J].J Biol Chem, 2004, 279 (9) :7370-7377.
    [2]Guo JS, Friedman SL.Toll-like receptor 4 signaling in liverinjury and hepatic fibrogenesis[J].Fibogenesis Tissue Re-pair, 2010, 3:21.
    [2]Guo JS, Friedman SL.Toll-like receptor 4 signaling in liverinjury and hepatic fibrogenesis[J].Fibogenesis Tissue Re-pair, 2010, 3:21.
    [3]Goodwin GH, Sanders C, Johns EW.A new group of chromatin-associated proteins with a high content of acidic and basic a-mino acids[J].Eur J Biochem, 1973, 38 (1) :14-19.
    [3]Goodwin GH, Sanders C, Johns EW.A new group of chromatin-associated proteins with a high content of acidic and basic a-mino acids[J].Eur J Biochem, 1973, 38 (1) :14-19.
    [4]Suda K, Takeuchi H, Ishizaka A, et al.High mobility groupbox chromosomal protein 1 as a new target for modulatingstress response[J].Surg Today, 2010, 40 (7) :592-601.
    [4]Suda K, Takeuchi H, Ishizaka A, et al.High mobility groupbox chromosomal protein 1 as a new target for modulatingstress response[J].Surg Today, 2010, 40 (7) :592-601.
    [5]Tang D, Kang R, Zeh III HJ 3rd, et al.High mobility groupbox 1, oxidative stress, and disease[J].Antioxid RedoxSignal, 2011, 14 (7) :1315-1335.
    [5]Tang D, Kang R, Zeh III HJ 3rd, et al.High mobility groupbox 1, oxidative stress, and disease[J].Antioxid RedoxSignal, 2011, 14 (7) :1315-1335.
    [6]Wang H, Bloom O, Zhang M, et al.HMG-1 as a late medi-ator of endotoxin lethality in mice[J].Science, 1999, 285 (5425) :248-251.
    [6]Wang H, Bloom O, Zhang M, et al.HMG-1 as a late medi-ator of endotoxin lethality in mice[J].Science, 1999, 285 (5425) :248-251.
    [7]Yang H, Ochani M, Li J, et al.Reversing established sepsiswith antagonists of endogenous high-mobility group box 1[J].Proc Natl Acad Sci U S A, 2004, 101 (1) :296-301.
    [7]Yang H, Ochani M, Li J, et al.Reversing established sepsiswith antagonists of endogenous high-mobility group box 1[J].Proc Natl Acad Sci U S A, 2004, 101 (1) :296-301.
    [8]张婷, 夏敏.高迁移率族蛋白B1信号转导通路的研究进展[J].医学综述, 2011, 17 (2) :195-198.
    [8]张婷, 夏敏.高迁移率族蛋白B1信号转导通路的研究进展[J].医学综述, 2011, 17 (2) :195-198.
    [9]Scaffidi P, Misteli T, Bianchi ME.Release of chromatin pro-tein HMGB1 by necrotic cells triggers inflammation[J].Na-ture, 2002, 418 (6894) :191-195.
    [9]Scaffidi P, Misteli T, Bianchi ME.Release of chromatin pro-tein HMGB1 by necrotic cells triggers inflammation[J].Na-ture, 2002, 418 (6894) :191-195.
    [10]Semino C, Angelini G, Poggi A, et al.NK/iDC interaction re-sults in IL-18 secretion by DCs at the synaptic cleft followedby NK cell activation and release of the DC maturation factorHMGB1[J].Blood, 2005, 106 (2) :609-616.
    [10]Semino C, Angelini G, Poggi A, et al.NK/iDC interaction re-sults in IL-18 secretion by DCs at the synaptic cleft followedby NK cell activation and release of the DC maturation factorHMGB1[J].Blood, 2005, 106 (2) :609-616.
    [11]Bonaldi T, Talamo F, Scaffidi P, et al.Monocytic cells hy-peracetylate chromatin protein HMGB1 to redirect it towardssecretion[J].EMBO J, 2003, 22 (20) :5551-5560.
    [11]Bonaldi T, Talamo F, Scaffidi P, et al.Monocytic cells hy-peracetylate chromatin protein HMGB1 to redirect it towardssecretion[J].EMBO J, 2003, 22 (20) :5551-5560.
    [12]Dumitriu IE, Baruah P, Manfredi AA, et al.HMGB1:guidingimmunity from within[J].Trends Immunol, 2005, 26 (7) :381-387.
    [12]Dumitriu IE, Baruah P, Manfredi AA, et al.HMGB1:guidingimmunity from within[J].Trends Immunol, 2005, 26 (7) :381-387.
    [13]Park JS, Arcaroli J, Yum HK, et al.Activation of gene ex-pression in human neutrophils by high mobility group box 1protein[J].Am J Physiol Cell Physiol, 2003, 284 (4) :C870-879.
    [13]Park JS, Arcaroli J, Yum HK, et al.Activation of gene ex-pression in human neutrophils by high mobility group box 1protein[J].Am J Physiol Cell Physiol, 2003, 284 (4) :C870-879.
    [14]Palumbo R, Galvez BG, Pusterla T, et al.Cells migrating tosites of tissue damage in response to the danger signalHMGB1 require NF-kappaB activation[J].J Cell Biol, 2007, 179 (1) :33-40.
    [14]Palumbo R, Galvez BG, Pusterla T, et al.Cells migrating tosites of tissue damage in response to the danger signalHMGB1 require NF-kappaB activation[J].J Cell Biol, 2007, 179 (1) :33-40.
    [15]Yang D, Chen Q, Yang H, et al.High mobility group box-1protein induces the migration and activation of human den-dritic cells and acts as an alarmin[J].J Leukoc Biol, 2007, 81 (1) :59-66.
    [15]Yang D, Chen Q, Yang H, et al.High mobility group box-1protein induces the migration and activation of human den-dritic cells and acts as an alarmin[J].J Leukoc Biol, 2007, 81 (1) :59-66.
    [16]Tsung A, Klune JR, Zhang X, et al.HMGB1 release inducedby liver ischemia involves Toll-like receptor 4 dependent re-active oxygen species production and calcium-mediated sig-naling[J].J Exp Med, 2007, 204 (12) :2913-2923.
    [16]Tsung A, Klune JR, Zhang X, et al.HMGB1 release inducedby liver ischemia involves Toll-like receptor 4 dependent re-active oxygen species production and calcium-mediated sig-naling[J].J Exp Med, 2007, 204 (12) :2913-2923.
    [17]Park JS, Gamboni-Robertson F, He Q, et al.High mobilitygroup box 1 protein interacts with multiple Toll like receptors[J].Am J Physiol Cell Physiol, 2006, 290 (3) :C917-C924.
    [17]Park JS, Gamboni-Robertson F, He Q, et al.High mobilitygroup box 1 protein interacts with multiple Toll like receptors[J].Am J Physiol Cell Physiol, 2006, 290 (3) :C917-C924.
    [18]Tsung A, Sahai R, Tanaka H, et al.The nuclear factorHMGB1 mediates hepatic injury after murine liver ischemia-reperfusion[J].J Exp Med, 2005, 201 (7) :1135-1143.
    [18]Tsung A, Sahai R, Tanaka H, et al.The nuclear factorHMGB1 mediates hepatic injury after murine liver ischemia-reperfusion[J].J Exp Med, 2005, 201 (7) :1135-1143.
    [19]Liu A, Dirsch O, Fang H, et al.HMGB1 in ischemic and non-ischemic liver after selective warm ischemia/reperfusion inrat[J].Histochem Cell Biol, 2011, 135 (5) :443-452.
    [19]Liu A, Dirsch O, Fang H, et al.HMGB1 in ischemic and non-ischemic liver after selective warm ischemia/reperfusion inrat[J].Histochem Cell Biol, 2011, 135 (5) :443-452.
    [20]Zhou RR, Zhao SS, Zou MX, et al.HMGB1 cytoplasmictranslocation in patients with acute liver failure[J].BMCGastroenterol, 2011, 11:21.
    [20]Zhou RR, Zhao SS, Zou MX, et al.HMGB1 cytoplasmictranslocation in patients with acute liver failure[J].BMCGastroenterol, 2011, 11:21.
    [21]刘洪波.乙型肝炎患者血清高迁移率族蛋白-1含量的检测及临床意义[J].中华肝脏病杂志, 2007, 15 (11) :812-814.
    [21]刘洪波.乙型肝炎患者血清高迁移率族蛋白-1含量的检测及临床意义[J].中华肝脏病杂志, 2007, 15 (11) :812-814.
    [22]Albayrak A, Uyanik MH, Cerrah S, et al.Is HMGB1 a newindirect marker for revealing fibrosis in chronic hepatitis and anew therapeutic target in treatment?[J].Viral Immunol, 2010, 23 (6) :633-638.
    [22]Albayrak A, Uyanik MH, Cerrah S, et al.Is HMGB1 a newindirect marker for revealing fibrosis in chronic hepatitis and anew therapeutic target in treatment?[J].Viral Immunol, 2010, 23 (6) :633-638.
    [23]Li L, Chen L, Hu L, et al.Nuclear factor high-mobilitygroup box1 mediating the activation of toll-like receptor 4signaling in hepatocytes in the early stage of nonalcoholic fat-ty liver disease in mice[J].Hepatology, 2011, Jul 11.doi:10.1002/hep.24552.[Epub ahead of print]
    [23]Li L, Chen L, Hu L, et al.Nuclear factor high-mobilitygroup box1 mediating the activation of toll-like receptor 4signaling in hepatocytes in the early stage of nonalcoholic fat-ty liver disease in mice[J].Hepatology, 2011, Jul 11.doi:10.1002/hep.24552.[Epub ahead of print]
    [24]Martin-Murphy BV, Holt MP, Ju C.The role of damage as-sociated molecular pattern molecules in acetaminophen-in-duced liver injury in mice[J].Toxicology Letter, 2010, 192 (3) :387-394.
    [24]Martin-Murphy BV, Holt MP, Ju C.The role of damage as-sociated molecular pattern molecules in acetaminophen-in-duced liver injury in mice[J].Toxicology Letter, 2010, 192 (3) :387-394.
    [25]Dragomir AC, Laskin JD, Laskin DL.Macrophage activationby factors released from acetaminophen-injured hepato-cytes:potential role of HMGB1[J].Toxicol Appl Pharma-col, 2011, 253 (3) :170-177.
    [25]Dragomir AC, Laskin JD, Laskin DL.Macrophage activationby factors released from acetaminophen-injured hepato-cytes:potential role of HMGB1[J].Toxicol Appl Pharma-col, 2011, 253 (3) :170-177.
    [26]Cheng BQ, Jia CQ, Liu CT, et al.Serum high mobility groupbox chromosomal protein 1 is associated with clinicopatho-logic features in patients with clinicopathologic features in pa-tients with hepatocellular carcinoma[J].Dig Liv Dis, 2008, 40 (6) :446-452.
    [26]Cheng BQ, Jia CQ, Liu CT, et al.Serum high mobility groupbox chromosomal protein 1 is associated with clinicopatho-logic features in patients with clinicopathologic features in pa-tients with hepatocellular carcinoma[J].Dig Liv Dis, 2008, 40 (6) :446-452.
    [27]王瀚锋, 徐晓东.高迁移率族蛋白B1肿瘤免疫调节作用及其机制[J].第二军医大学学报, 2010, 31 (12) :1359-1362.
    [27]王瀚锋, 徐晓东.高迁移率族蛋白B1肿瘤免疫调节作用及其机制[J].第二军医大学学报, 2010, 31 (12) :1359-1362.
    [28]Tang D, Kang R, Zeh HJ, et al.High-mobility group box 1and cancer[J].Biochim Biophys Acta, 2010, 1799 (1-2) :131-140.
    [28]Tang D, Kang R, Zeh HJ, et al.High-mobility group box 1and cancer[J].Biochim Biophys Acta, 2010, 1799 (1-2) :131-140.
    [29]Liang X, Chavez AR, Schapiro NE, et al.Ethyl pyruvate ad-ministration inhibits hepatic tumor growth[J].J Leukoc Bi-ol, 2009, 86 (3) :599-607.
    [29]Liang X, Chavez AR, Schapiro NE, et al.Ethyl pyruvate ad-ministration inhibits hepatic tumor growth[J].J Leukoc Bi-ol, 2009, 86 (3) :599-607.
    [30]Apetoh L, Ghiringhelli F, Tesniere A, et al.The interactionbetween HMGB1 and TLR4 dictates the outcome of antican-cer chemotherapy and radiotherapy[J].Immunol Rev, 2007, 220 (1) :47-59.
    [30]Apetoh L, Ghiringhelli F, Tesniere A, et al.The interactionbetween HMGB1 and TLR4 dictates the outcome of antican-cer chemotherapy and radiotherapy[J].Immunol Rev, 2007, 220 (1) :47-59.
    [31]Apetoh L, Ghiringhelli F, Tesniere A, et al.Toll-like recep-tor 4-dependent contribution of the immune system to anti-cancer chemotherapy and radiotherapy[J].Nat Med, 2007, 13 (9) :1050-1059.
    [31]Apetoh L, Ghiringhelli F, Tesniere A, et al.Toll-like recep-tor 4-dependent contribution of the immune system to anti-cancer chemotherapy and radiotherapy[J].Nat Med, 2007, 13 (9) :1050-1059.
    [32]Klune JR, Dhupar R, Cardinal J, et al.HMGB1:endogenousdanger signaling[J].Mol Med, 2008, 14 (7-8) :476-484.
    [32]Klune JR, Dhupar R, Cardinal J, et al.HMGB1:endogenousdanger signaling[J].Mol Med, 2008, 14 (7-8) :476-484.
    [33]Liu A, Jin H, Dirsch O, et al.Release of danger signal as amarker of organ quality during storage of liver:a potentialmarker of organ damage?[J].Mediators Inflamm, 2010:436145.Epub 2010 Dec 21.
    [33]Liu A, Jin H, Dirsch O, et al.Release of danger signal as amarker of organ quality during storage of liver:a potentialmarker of organ damage?[J].Mediators Inflamm, 2010:436145.Epub 2010 Dec 21.
    [34]Ilmakunnas M, Tukiainen EM, Rouhiainen A, et al.Highmobility group box 1 protein as a marker of hepatocellular in-jury in human liver transplantation[J].Liver Transpl, 2008, 14 (10) :1517-1525.
    [34]Ilmakunnas M, Tukiainen EM, Rouhiainen A, et al.Highmobility group box 1 protein as a marker of hepatocellular in-jury in human liver transplantation[J].Liver Transpl, 2008, 14 (10) :1517-1525.
    [35]Guo J, Friedman SL.Hepatic fibrogenesis[J].Semin LiverDis, 2007, 27 (4) :413-426.
    [35]Guo J, Friedman SL.Hepatic fibrogenesis[J].Semin LiverDis, 2007, 27 (4) :413-426.
    [36]Friedman SL.Hepatic fibrosis-overview[J].Toxicology, 2008, 254 (3) :120-129.
    [36]Friedman SL.Hepatic fibrosis-overview[J].Toxicology, 2008, 254 (3) :120-129.
    [37]Fehrenbach H, Weiskirchen R, Kasper M, et al.Up-regula-ted expression of the receptor for advanced glycation endproducts in cultured rat hepatc stellate cells during transdif-ferentiation to myofibroblasts[J].Hepatology, 2001, 34 (5) :943-952.
    [37]Fehrenbach H, Weiskirchen R, Kasper M, et al.Up-regula-ted expression of the receptor for advanced glycation endproducts in cultured rat hepatc stellate cells during transdif-ferentiation to myofibroblasts[J].Hepatology, 2001, 34 (5) :943-952.
    [38]Lohwasser C, Neureiter D, Popov Y, et al.Role of the re-ceptor for advanced glycation end products in hepatic fibrosis[J].WJG, 2009, 15 (46) :5789-5798.
    [38]Lohwasser C, Neureiter D, Popov Y, et al.Role of the re-ceptor for advanced glycation end products in hepatic fibrosis[J].WJG, 2009, 15 (46) :5789-5798.
    [39]Seki E, De Minicis S, Osterreicher CH, et al.TLR4 en-hances TGF-beta signaling and hepatic fibrosis[J].NatMed, 2007, 13 (11) :1324-1332.
    [39]Seki E, De Minicis S, Osterreicher CH, et al.TLR4 en-hances TGF-beta signaling and hepatic fibrosis[J].NatMed, 2007, 13 (11) :1324-1332.
    [40]Kao, Jawan B, Goto S, et al.High-mobility group box 1protein activates hepatic stellate cells in vitro[J].TransplProc, 2008, 40 (8) :2704-2705.
    [40]Kao, Jawan B, Goto S, et al.High-mobility group box 1protein activates hepatic stellate cells in vitro[J].TransplProc, 2008, 40 (8) :2704-2705.
    • Relative Articles

  • Relative Articles

    [1]Shiyu YUAN, Huanhuan YANG, Yingmei TANG. Role of T-cell immunoglobulin and mucin domain-containing molecule 3 in the development and progression of liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(6): 1275-1280. doi: 10.12449/JCH240632
    [2]Sisi WANG, Yaru WANG, Rui LIU, Jie QIN. Mechanism of action and potential therapeutic targets of ferroptosis suppressor protein 1 in liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(7): 1493-1497. doi: 10.12449/JCH240731
    [3]Chenlu HAN, Haijun LIANG, Daokun YANG, Haiyan CHANG, Shuai WEI, Xingwei WANG, Haili GAO. Expression levels of serum high-mobility group box 1， soluble CD163， and prostaglandin E2 in patients with hepatitis B virus-related chronic-on-acute liver failure and their value in predicting prognosis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1130-1135. doi: 10.12449/JCH240610
    [4]Yan YANG, Feilin GE, Qian HUANG, Xinyue ZHANG, Rui ZENG, Xiaohe XIAO, Zhaofang BAI, Qin SUN. Mechanism of action of nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome in liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(4): 942-946. doi: 10.3969/j.issn.1001-5256.2022.04.041
    [5]Laying ZHANG, Mingkai CHEN. Research advances in the mechanism of action of TRPV4 ion channel protein in liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(1): 224-227. doi: 10.3969/j.issn.1001-5256.2022.01.040
    [6]Zhengguang LIAO, Shihui WEI, Danyu DU, Li SUN, Shengtao YUAN. Role of lipocalin-2 in the development and progression of liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(9): 2177-2181. doi: 10.3969/j.issn.1001-5256.2022.09.044
    [7]Xia WU, Xiaoning ZHU, Yurong ZHANG, Yue YIN, Mengyun PENG, Ding ZHENG, Jing WANG. Mechanism of action of suppressor of cytokine signaling 1 in the development and progression of liver inflammatory diseases[J]. Journal of Clinical Hepatology, 2021, 37(4): 973-976. doi: 10.3969/j.issn.1001-5256.2021.04.055
    [8]Yang ShangQing, Yang DongLiang, Liu Jia. Role of matrix metalloproteinases-2 and matrix metalloproteinases-9 in the development and progression of chronic liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(10): 2364-2369. doi: 10.3969/j.issn.1001-5256.2020.10.045
    [9]Wang ShanShan, Zhang QingShan, Zhao SuXian, Kong LingBo, Ji Lei, Kong Li. The immunoregulatory effect of tumor necrosis factor-alpha-induced protein 8-like 2 in different liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(2): 460-463. doi: 10.3969/j.issn.1001-5256.2020.02.050
    [10]Ye QianLing, Mao DeWen, Wang MingGang, Wang Na. Role of NLRP3 inflammasome in the development and progression of liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(10): 2346-2350. doi: 10.3969/j.issn.1001-5256.2019.10.048
    [11]Pan SiYu, Wang ZhiXin, ZHOU Ying, Wang Tao, Yin Jie, Wang Qiang, Fan HaiNing. Function and mechanism of action of the PD-1/PD-L1 pathway in liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(3): 672-676. doi: 10.3969/j.issn.1001-5256.2019.03.050
    [12]Pu MinJing, Zhao HongXian, Bo Chao, Zhou XiangYu, Chen Xia. Role and mechanism of the high-mobility group box 1/Toll-like receptor 9 signaling pathway in intestinal mucosal barrier injury in severe acute pancreatitis[J]. Journal of Clinical Hepatology, 2019, 35(5): 1037-1040. doi: 10.3969/j.issn.1001-5256.2019.05.020
    [13]Yang XinYing, Kang FuBiao, Ye LiHong, Dai ErHei, Sun DianXing. Level of high-mobility group box 1 in patients with chronic hepatitis B and liver cirrhosis and its clinical significance[J]. Journal of Clinical Hepatology, 2018, 34(9): 1901-1904. doi: 10.3969/j.issn.1001-5256.2018.09.015
    [14]Wei FengXian, Liu Zhao, Geng Jie, Su GuoHong, Chen Mo, Wang ManCai, Cao WeiJia, Zhang YouCheng. Research advances in association between Golgi protein 73 and liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(8): 1595-1598. doi: 10.3969/j.issn.1001-5256.2017.08.040
    [15]Li Chen, Chen Jing, Liu HongLing, Zhu Bing, Zang Hong, You ShaoLi, Xin ShaoJie. One case of primary hepatic amyloidosis[J]. Journal of Clinical Hepatology, 2013, 29(10): 790-792. doi: 10.3969/j.issn.1001-5256.2013.10.017
    [16]Zhang Qian, Han Tao. Research progress in advanced oxidation protein products in liver diseases[J]. Journal of Clinical Hepatology, 2013, 29(8): 581-584. doi: 10.3969/j.issn.1001-5256.2013.08.007
    [17]Xu Fang, Liu Jun, Gao PuJun. Severe liver injury with hyperthyroidism : a case report[J]. Journal of Clinical Hepatology, 2011, 27(10): 1096-1098.
    [18]Niu ChunYan, Zheng JianYun, Li Lei, Gao BaoHua, Liu Bing, Luo JianMei. The expression and significance of HMGB1 in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(8): 807-809.
    [19]Gao BaoHua, Wang Wen, Niu ChunYan, Zheng JianYun, Liu Bing, Luo JianMei. The expression of HMGB1 in hepatocellular carcinoma, paracancerous liver tissue and its significance[J]. Journal of Clinical Hepatology, 2011, 27(8): 850-853.
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (3439) PDF downloads(754) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1794]YesterdayPV[3166]TodayIP[277]TodayPV[508]Online[8]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return